[Form 4] Natera, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Natera, Inc. (NTRA) insider sale under 10b5-1 plan. On 09/02/2025 Solomon Moshkevich, President, Clinical Diagnostics, reported three open-market sell transactions totaling 3,000 shares executed under a Rule 10b5-1 plan adopted on 11/26/2024. The sales were reported at weighted-average prices of $165.6862, $166.39, and $167.7145, with underlying per-trade price ranges of $165.09–$168.21. Beneficial ownership reported after the trades declined from 122,569 to 120,859 shares across the transactions. The Form 4 was signed by an attorney-in-fact on 09/05/2025.

Positive

• Transactions executed under a Rule 10b5-1 plan adopted on 11/26/2024, which supports compliance with insider trading rules
• Complete disclosure of weighted-average prices and price ranges for the multiple executions

Negative

• Insider sold 3,000 shares on 09/02/2025, reducing reported direct holdings from 122,569 to 120,859 shares
• Sales may be viewed negatively by some investors despite being pre-planned (no inference of intent is made in this filing)

Insights

Securities Analyst

TL;DR: Insider executed pre-planned sales totaling 3,000 shares under a 10b5-1 plan; ownership decreased modestly.

The reported transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on 11/26/2024, which provides affirmative defense to insider trading claims when properly established. The sales on 09/02/2025 amounted to 3,000 shares sold across three tranches at weighted-average prices between $165.69 and $167.71, reducing reported direct holdings from 122,569 to 120,859 shares. As these sales were pre-planned and represent a small absolute share count for an officer-level holder, the disclosure is routine from a governance and compliance perspective.

Corporate Governance Expert

TL;DR: Transactions appear procedural under a 10b5-1 plan; no new governance issues disclosed.

The Form 4 clearly states the trades were effectuated under a 10b5-1 plan adopted 11/26/2024, and provides weighted-average price ranges across multiple executions. The filing includes standard attestations and an attorney-in-fact signature dated 09/05/2025. There is no indication in this filing of departures, option exercises, or non-routine related-party transactions that would raise immediate governance concerns.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Moshkevich Solomon

(Last) (First) (Middle)

C/O NATERA, INC.

13011 MCCALLEN PASS BUILDING A SUITE 100

(Street)

AUSTIN TX 78753

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Natera, Inc. [ NTRA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	PRESIDENT, CLINICALDIAGNOSTICS

3. Date of Earliest Transaction (Month/Day/Year)
09/02/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/02/2025		S		1,290(1)	D	$165.6862(2)	122,569	D
Common Stock	09/02/2025		S		500(1)	D	$166.39(3)	122,069	D
Common Stock	09/02/2025		S		1,210(1)	D	$167.7145(4)	120,859	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024.

2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $165.09 to $166.06 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $166.09 to $166.60 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

4. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $167.41 to $168.21 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

	/s/ Vincent Fontanilla, Attorney-in-Fact	09/05/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did NTRA insider Solomon Moshkevich report on Form 4?

The filing reports three sell transactions on 09/02/2025 totaling 3,000 shares executed under a Rule 10b5-1 trading plan.

How much did the insider sell and what were the prices?

Sales were 1,290, 500, and 1,210 shares at weighted-average prices of $165.6862, $166.39, and $167.7145; execution price ranges spanned $165.09–$168.21.

When was the 10b5-1 plan for these sales adopted?

The Rule 10b5-1 trading plan was adopted on 11/26/2024, as disclosed in the Form 4.

How did the insider’s beneficial ownership change after the sales?

Reported direct beneficial ownership decreased from 122,569 shares to 120,859 shares following the transactions.

Who signed the Form 4?

The Form 4 was signed by Vincent Fontanilla, Attorney-in-Fact on 09/05/2025.